Published in Cancer Biol Ther on February 20, 2014
Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib. Sci Rep (2014) 0.83
Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents. Oncol Lett (2016) 0.80
Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines. Oncotarget (2015) 0.78
Targeted therapy in sarcomas other than GIST tumors. J Surg Oncol (2014) 0.78
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget (2017) 0.77
Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol (2017) 0.75
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis (2009) 2.15
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res (2011) 2.13
Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther (2010) 1.31
Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. Mol Pharmacol (2013) 1.23
Valproic acid as anti-cancer drug. Curr Pharm Des (2007) 1.11
HDAC inhibitors and cancer therapy. Prog Drug Res (2011) 1.11
Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma. Crit Rev Oncol Hematol (2013) 1.05
Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Mol Carcinog (2011) 1.05
Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. Br J Cancer (2013) 1.05
Novel targets for VEGF-independent anti-angiogenic drugs. Expert Opin Investig Drugs (2012) 0.95
Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. PLoS One (2012) 0.95
Acetylation: a novel link between double-strand break repair and autophagy. Cancer Res (2012) 0.93
Valproic acid promotes neuronal differentiation by induction of neuroprogenitors in human bone-marrow mesenchymal stromal cells. Neurosci Lett (2013) 0.92
Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells. Am J Pathol (2013) 0.91
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. Cancer Biol Ther (2013) 0.89
Pazopanib in sarcomas: expanding the PALETTE. Curr Opin Oncol (2013) 0.85
Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer. J Cancer Res Clin Oncol (2013) 0.83
First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile. Cancer Biol Ther (2013) 0.82
PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. Cancer Biol Ther (2014) 0.92
HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells. Cancer Biol Ther (2013) 0.90